Clinical Research Directory
Browse clinical research sites, groups, and studies.
IIT2023-09-Chung-UpfrontTAD: Upfront TAD/SNB in Patients With Breast Cancer With Nodal Metastases
Sponsor: Alice Chung
Summary
The purpose of the study is to determine the recurrence rates and survival of patients with clinical T1-2N0 ER+/Her2- invasive breast cancer who have biopsy proven image detected nodal disease treated with upfront lumpectomy or mastectomy with TAD followed by adjuvant therapy. This is a prospective, single arm phase II clinical trial. Patients will be screened and enrolled per eligibility criteria. Patient, tumor, and treatment data will be documented.
Official title: IIT2023-09-Chung-UpfrontTAD: Upfront TAD/SNB in Patients With Clinical T1-2N0 ER+ Her2- Breast Cancer With Ultrasound Detected Nodal Metastases
Key Details
Gender
FEMALE
Age Range
45 Years - Any
Study Type
INTERVENTIONAL
Enrollment
45
Start Date
2024-04-07
Completion Date
2031-04
Last Updated
2025-12-10
Healthy Volunteers
No
Conditions
Interventions
Breast Surgery (BCS or mastectomy) with TAD/SNB
Breast surgery (BCS or mastectomy) with TAD/SNB \& Adjuvant Radiation therapy
Adjuvant Radiation Therapy
Breast surgery (BCS or mastectomy) with TAD/SNB \& Adjuvant Radiation therapy
Locations (3)
Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute
Los Angeles, California, United States
CS Cancer at Huntington Cancer Center
Pasadena, California, United States
CS Cancer at Valley Oncology Medical Group
Tarzana, California, United States